Lansoprazole Sandoz

Lansoprazole, the active ingredient in Lansoprazole Sandoz, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is prescribed for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazole Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulations.

Lansoprazole is a proton pump inhibitor used to treat acid‑related gastrointestinal disorders. By suppressing gastric acid secretion, it addresses the underlying cause of several upper‑GI conditions.

- Gastro‑oesophageal reflux disease (GERD): reduces gastric acid exposure, relieving heartburn and regurgitation. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotics by decreasing stomach acidity. - Erosive esophagitis: allows damaged esophageal tissue to recover by limiting acid reflux. - Zollinger‑Ellison syndrome: controls hypergastrinemia‑induced acid hypersecretion.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Diarrhea: loose stools that may occur during the first weeks of therapy. - Nausea: transient feeling of queasiness, usually mild. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased gas causing bloating. - Constipation: reduced bowel movements, may be relieved with diet.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing requiring immediate medical attention. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea and abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat, or seizures with prolonged use.

Before initiating Lansoprazole therapy, consider several precautionary measures to ensure safe and effective use. - Assess renal function: adjust therapy in patients with severe impairment. - Monitor magnesium levels: long‑term use can lead to hypomagnesemia. - Review concomitant medications: avoid use with drugs known to have reduced efficacy. - Use with caution in hepatic disease: dose may need adjustment in severe liver impairment. - Inform patients about potential rebound acid hypersecretion after discontinuation: gradual taper may be required. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Lansoprazole can affect the pharmacokinetics of several medicines; awareness of key interactions helps prevent therapeutic failures or toxicity.

Major Interactions (Avoid): - Clopidogrel: reduced conversion to active metabolite, decreasing antiplatelet effect. - Atazanavir: decreased absorption leading to loss of antiviral efficacy. - Methotrexate: increased serum concentrations, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Digoxin: higher plasma levels may occur, necessitating dose adjustment. - Diazepam: enhanced sedation due to increased exposure.